Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis

Medicine and Dentistry

• Multiple Sclerosis 100%
• Patient 100%
• Inpatient 100%
• Lesion 85%
• Positron Emission Tomography 57%
• Mitochondrial Membrane Transport Protein 42%
• Iron 42%
• Immunocompetent Cell 42%
• Follow up 28%
• Magnetic Resonance Imaging 28%
• Carbon 11 28%
• Cell Activation 28%
• Radioligand 14%
• Gender 14%
• Age 14%
• Cell Activity 14%
• White Matter Lesion 14%

Neuroscience

• Positron Emission Tomography 100%
• Multiple Sclerosis 100%
• Translocator Protein 75%
• White Matter 75%
• Magnetic Resonance Imaging 50%
• Brain 50%
• Cell Activation 50%
• Thalamus 50%
• Radioligand 25%

Immunology and Microbiology

• Teriflunomide 100%
• Thalamus 50%
• Brain Size 50%
• Relapsing Remitting Multiple Sclerosis 50%
• Gender 25%
• Cell Activity 25%